Fig. 4: ASS1 knockdown in ILC cells. | Cell Death & Disease

Fig. 4: ASS1 knockdown in ILC cells.

From: Invasive lobular carcinoma: integrated multi-omics analysis reveals silencing of Argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance

Fig. 4

MB134 and SUM44 cells were transduced with plasmids expressing shRNA targeting ASS1 or the corresponding empty vector to produce shASS1 and control (pLKO) cell lines. A qRT-PCR analysis showing ASS1 expression, and B Western blot and densitometry analysis of ASS1 protein levels in ASS1 knockdown (shASS1) vs. pLKO (control) MB134 and SUM44 cell lines. C Dose response to tamoxifen and IC50 of tamoxifen in ASS1 knockdown (shASS1) vs. pLKO (control) MB134 (left panel) and SUM44 cell lines (right panel), assessed using the automated cell counting method. D Comparison of growth kinetics of shASS1 vs. pLKO derivatives of MB134 (left panel) and SUM44 cell lines (right panel). Fold change in growth is normalized to day 0 at each time point over 72 h. E Overall survival analysis of all breast cancer patients in relation to ASS1 expression using the METABRIC dataset. F Overall survival analysis of ILC patients who received endocrine therapy in relation to ASS1 expression using the METABRIC dataset. G Overall survival analysis of breast cancer patients who received endocrine therapy in relation to ASS1 expression using the K–M plotter dataset. ****p < 0.0001, ***p ≤ 0.001, **P ≤ 0.01, *p < 0.05.

Back to article page